



Walter+Eliza Hall

Institute of Medical Research


DISCOVERIES FOR HUMANITY

Targeting plasmacytoid dendritic cells as treatment for systemic lupus erythematosus

Walter and Eliza Hall Institute of Medical Research

Melbourne, Australia

Systemic lupus erythematosus (SLE)



- **Chronic autoimmune disease** of the connective tissue.
 - Lupus nephritis, inflammation of the kidney, is a major contributor to morbidity and mortality among SLE patients
- SLE affects **20-40 people out of every 100,000**
 - Most prevalent in non-Caucasians and in women, incidence is highest between 15–44 years.
 - **Currently no cure** with treatments predominantly aimed at easing symptoms.
 - Mainstay therapeutic options delivered by off-label therapies with undesirable safety profiles



Bhattacharya, 2011; Borchers et al., 2012; O'Neill and Cervera, 2010; Danchenko et al., 2006
<https://ghr.nlm.nih.gov/condition/systemic-lupus-erythematosus> (accessed 24/09/2018)

Plasmacytoid dendritic cells – a potential SLE treatment

- **Plasmacytoid DCs (pDCs)** are over-activated in SLE patients and play an important role in disease pathogenesis
 - Drive disease through over-production of interferons (IFN)
- Mature pDCs and IFN- α are already targets for immunotherapy
 - e.g. CSL362 anti-IL-3R α mAb and Anifrolumab, Astra Zeneca's anti-IFN- α mAb
- **Can pDCs be targeted at the developmental stage?**

Plasmacytoid dendritic cells – a potential SLE treatment




- Researchers at WEHI have developed an *in vitro* system to generate mouse DCs
 - Produces large numbers of DCs (60-100 million from one mouse) expressing appropriate cell surface markers



Naik, Proietto, *et al.* 2005
Naik *et al.* 2010




pDC inhibitor program at WEHI

WEHI researchers have identified a novel inhibitor that **effectively depletes human pDCs**



pDC inhibitor program at WEHI

Research in mice showed that the inhibitor, and backup compounds, **block pDC development** (but not survival) and **ameliorate IFN production**





pDC inhibitor program at WEHI

Currently:

1. Undertaking medicinal chemistry studies to identify SAR and mode of action
2. Refining the compound (stability) to allow for ***in vivo* validation** in genetic and human xenograft models of SLE



Dr Shalin Naik, PhD

- Immunologist
- Research group studies how immune cells develop from hematopoietic stem cells



Associate Professor Guillaume Lessene, PhD

- Medicinal chemist
- Research group focuses on cellular pathways controlling cell death

What we want/partnering opportunities

We are seeking a **co-development partner** to:

1. Identify the target of the inhibitor
 - Cross-linking immunoprecipitation (CLIP): variant with UV cleavable linker available, assay requires further optimisation
 - Cellular Thermal Shift Assay (CETSA)
2. Develop a lead candidate which would allow testing of *in vivo* efficacy and safety
 - Preclinical validation pathways using genetic and human xenograft models of SLE established at WEHI
 - Real time 4D 2-photon confocal microscopy available for *in vivo* efficacy studies

Goal: Positioning the technology for pre-clinical toxicity program and IND filing.



Walter+Eliza Hall

Institute of Medical Research

DISCOVERIES FOR HUMANITY



Walter and Eliza Hall Institute of Medical Research

Business Development Office

1G Royal Parade

Parkville, Victoria 3052

Australia

www.wehi.edu.au/businessdevelopment

Clare Morgan, PhD

Business Development Manager

cmorgan@wehi.edu.au

Anne-Laure Puaux, PhD

Head of Commercialisation

puaux.a@wehi.edu.au